atypical antipsychotic agent; second generation antipsychotic

From Aaushi
Jump to navigation Jump to search
[1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22]

Indications

Benefit/risk

Dosage

Monitor

Adverse effects

* RR in demented patients

Notes

  • atypical antipsychotics may not be more effective than older agents in the treatment of schizophrenia
  • all agents are discontinued more frequently than not[5]

More general terms

More specific terms

Additional terms

References

  1. ↑ UCLA Intensive Course in Geriatric Medicine & Board Review, Marina Del Ray, CA, Sept 12-15, 2001
  2. ↑ 2.0 2.1 2.2 Prescriber's Letter 10(11):62 2003
  3. ↑ 3.0 3.1 3.2 Prescriber's Letter 11(3):13 2004 Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=200306&pb=PRL (subscription needed) http://www.prescribersletter.com
  4. ↑ 4.0 4.1 FDA Public Health Advisory Deaths with Antipsychotics in Elderly Patients with Behavioral Disturbances http://www.fda.gov/cder/drug/advisory/antipsychotics.htm http://www.fda.gov/medwatch/SAFETY/2005/safety05.htm#atypical
    Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA. 2005 Oct 19;294(15):1934-43. PMID: https://www.ncbi.nlm.nih.gov/pubmed/16234500
  5. ↑ 5.0 5.1 Lieberman JA et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005 Sep 22; 353:1209-23. PMID: https://www.ncbi.nlm.nih.gov/pubmed/16172203
  6. ↑ 6.0 6.1 Douglas IJ and Smeeth L. Exposure to antipsychotics and risk of stroke: Self controlled case series study. BMJ 2008 Aug 28; 337:a1227. PMID: https://www.ncbi.nlm.nih.gov/pubmed/18755769
  7. ↑ Prescriber's Letter 16(10): 2009 Comparison of Atypical Antipsychotics Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=251010&pb=PRL (subscription needed) http://www.prescribersletter.com
  8. ↑ Prescriber's Letter 17(1): 2010 Atypical Antipsychotics in Kids Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=260102&pb=PRL (subscription needed) http://www.prescribersletter.com
  9. ↑ Prescriber's Letter 17(2): 2010 Comparison of Atypical Antipsychotics Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=260206&pb=PRL (subscription needed) http://www.prescribersletter.com
  10. ↑ 10.0 10.1 Maher AR et al. Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults. JAMA 2011 Sep 28; 306:1359 PMID: https://www.ncbi.nlm.nih.gov/pubmed/21954480
  11. ↑ Prescriber's Letter 18(12): 2011 CHART: Off-Label Use of Atypical Antipsychotics in Adults CHART: Comparison of Atypical Antipsychotics Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=271207&pb=PRL (subscription needed) http://www.prescribersletter.com
  12. ↑ 12.0 12.1 12.2 Deprecated Reference
  13. ↑ 13.0 13.1 Jeste DV. Tardive dyskinesia rates with atypical antipsychotics in older adults. J Clin Psychiatry. 2004;65 Suppl 9:21-4. PMID: https://www.ncbi.nlm.nih.gov/pubmed/15189108
  14. ↑ 14.0 14.1 14.2 Romo-Nava F et al. Melatonin attenuates antipsychotic metabolic effects: An eight-week randomized, double-blind, parallel-group, placebo- controlled trial. Bipolar Disord 2014 Mar 17 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/24636483 <Internet> http://onlinelibrary.wiley.com/doi/10.1111/bdi.12196/abstract
  15. ↑ 15.0 15.1 Vigen CL, Mack WJ, Keefe RS et al Cognitive effects of atypical antipsychotic medications in patients with Alzheimer's disease: outcomes from CATIE-AD. Am J Psychiatry. 2011 Aug;168(8):831-9 PMID: https://www.ncbi.nlm.nih.gov/pubmed/21572163
  16. ↑ 16.0 16.1 16.2 Hwang YJ, Dixon SN, Reiss JP et al Atypical Antipsychotic Drugs and the Risk for Acute Kidney Injury and Other Adverse Outcomes in Older Adults: A Population-Based Cohort Study. Ann Intern Med. 2014;161(4):242-248 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/25133360 <Internet> http://annals.org/article.aspx?articleid=1897100
  17. ↑ 17.0 17.1 Fraser LA et al. Falls and fractures with atypical antipsychotic medication use: A population-based cohort study. JAMA Intern Med 2015 Jan 12 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/25581312 <Internet> http://archinte.jamanetwork.com/article.aspx?articleid=2089230
  18. ↑ 18.0 18.1 Maust DT, Kim HM, Seyfried LS et al. Antipsychotics, other psychotropics, and the risk of death in patients with dementia: Number needed to harm. JAMA Psychiatry 2015;72(5):438-445. Mar 18; PMID: https://www.ncbi.nlm.nih.gov/pubmed/25786075
  19. ↑ 19.0 19.1 Weintraub D et al. Association of antipsychotic use with mortality risk in patients with Parkinson disease. JAMA Neurol 2016 Mar 21 PMID: https://www.ncbi.nlm.nih.gov/pubmed/26999262
  20. ↑ 20.0 20.1 Geriatric Review Syllabus, 9th edition (GRS9) Medinal-Walpole A, Pacala JT, Porter JF (eds) American Geriatrics Society, 2016
  21. ↑ Peuskens J, Pani L, Detraux J, De Hert M. The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review. CNS Drugs. 2014 May;28(5):421-53. Review. PMID: https://www.ncbi.nlm.nih.gov/pubmed/24677189 Free PMC Article
  22. ↑ Rognoni C, Bertolani A, Jommi C. Second-generation antipsychotic drugs for patients with schizophrenia: systematic literature review and meta-analysis of metabolic and cardiovascular side effects. Clin Drug Investig. 2021;41:303-319. PMID: https://www.ncbi.nlm.nih.gov/pubmed/33686614
Retrieved from "https://aaushi.info/w/index.php?title=A18590&oldid=1203746"